ARTICLE | Clinical News
Balugrastim regulatory update
November 25, 2013 8:00 AM UTC
Teva said it withdrew a BLA for balugrastim, a long-acting recombinant human G-CSF fused to human albumin that had been under FDA review for neutropenia. The company, which submitted the BLA in Decemb...